Carfilzomib reverses pulmonary arterial hypertension

Conclusion
The addition of anti-tumour agents such as CFZ along with cardioprotectants to currently available vasodilators may be a promising way to improve PAH therapy.

Source: Cardiovascular Research - April 18, 2016 Category: Cardiology Authors: Wang, X., Ibrahim, Y. F., Das, D., Zungu-Edmondson, M., Shults, N. V., Suzuki, Y. J. Tags: Integrative physiology and pathophysiology Source Type: research